Atlas Trials

Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment

Clinical trial NCT07206264 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07206264
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2025-10-01
Primary completion
2027-12-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.